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Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: 
a linked-record cohort study  
Supplementary Appendix 
Supplementary Methods 
Modified Charlson Comorbidity Scores 
Comorbidity scores were derived using a modification of the Charlson Comorbidity 
Index (CCI) 1. Individual scores were calculated as the sum of weighted scores for 
each of 17 disease conditions identified from hospital admission data using ICD-10 
codes for secondary diagnosis fields (DIAG2-DIAG14) 2,3 (supplementary table 1).  
Laboratory assays 
Between January 1998 and April 2004 TSH receptor antibodies (TRAbs) were 
measured with a 2nd generation radioimmunoassay (RIA) based on inhibition of 
labelled TSH binding to TSH receptor coated tubes, RSR Limited, Cardiff 4,5. The 
assay reference ranges were: <1.0, negative, 1.0-1.5 borderline >1.5, positive with 
analytical range of 1—40 U/L, and lower detection limit of 0.33 U/L. The sensitivity of 
the assay was 92.0% with specificity of 100%. Between April 2004 and December 
2013, TRAbs were measured with a 2nd generation RIA which was also based on 
inhibition of radio-labelled TSH binding to TSH receptor coated tubes, B.R.A.H.M.S. 
TRAK human, Thermo Scientific 6. The assay reference ranges were: <1.0, negative, 
1.0-1.5 borderline, and >1.5, positive, with analytical range of 1—40 U/L, functional 
sensitivity of 1.0 +/- 0.2 U/L and analytical sensitivity of 0.3 U/L. The sensitivity of the 
assay was 98.8% with specificity of 99.6%. The assay principles, performance, and 
reference ranges for thyroid function tests (FT4 and TSH) are presented in 
supplementary table 2. To account for differences in assay methods, FT4 was 
transformed to multiples of the upper limit of the assay reference range (ULN) and 
TSH was categorised as low, normal or high-TSH according to the assay reference 
range. 
Restricted Cubic Spline Regression 
We modelled a potential non-linear relationship between the FT4 concentration at one 
year and mortality or MACE using restricted cubic spline regressions. Cubic splines 
allow flexible smooth transformations of the relationship between a quantitative 
covariate and an outcome 7. We used the mkspline co-mmand in Stata to set 4 equally-
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spaced knots at percentiles 5, 35, 65 and 95 according to the recommendation by 
Harrell 8. Varying the positions of the knots did not significantly influence our estimates. 
The reference values were set at the FT4 assay upper limit (x 1.0). Predicted hazard 
ratios (HR) were derived from Cox regression models adjusted for age, gender, year 
of diagnosis, baseline TRAb concentration, and comorbidity. We used the xblc post-
estimation package in Stata to plot the regression between FT4 and log HR for 
mortality/MACE. Models were fitted for the whole cohort and then stratified by 
treatment. P values for non-linearity were obtained using likelihood ratio tests. We also 
used cubic splines to model longitudinal change in FT4 concentration in the first year 
of treatment with cubic knots set at 0, 3, 6, 9, and 12 months.  
Missing data imputation 
Serial thyroid function tests were available for patients with Graves’ disease but not 
for the control population. Thyroid function tests were missing in 29% of patients. One-
year TSH was available in 80% of patients with serial thyroid function tests equivalent 
to 57% of the eligible landmark cohort. All other variables had complete data. Missing 
thyroid tests were due to lack of electronic access and linkage of laboratory data to 
the SAIL databank from some laboratories at various study time segments. Where 
laboratory linkage occurred, thyroid tests were available in >90% of patients in clinics 
served by the laboratory, reducing the likelihood of confounding by data not missing 
at random.  
The characteristics of patients with missing and non-missing thyroid tests is shown in 
supplementary table 3. Patients with missing tests were older (49 vs 47 years) and 
missing tests were more frequent in patients treated with antithyroid drugs compared 
to radioiodine or surgery (37% vs 3% vs 16%, P<0.001). Patients with missing tests 
also had lower TRAb levels (median 5.8 vs 7.8 IU/L) but in logistic regression, the only 
factors associated with thyroid test missingness were older age (OR 1.01, 95%CI 1.00, 
1.02 per year increase in age) and treatment with antithyroid drugs (OR 2.28, 95%CI 
1.61, 3.23, antithyroid drugs vs radioiodine/Surgery). Missingness was not associated 
with sex, comorbidity, TRAB concentration, mortality or MACE. Thus, we assumed the 
data were not ‘Missing Completely at Random, (MCAR)’ but were ‘Missing at Random, 
(MAR)’.  
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In the one-year TSH analysis we addressed missing tests using multiple variable 
imputation by chained equations 9. The imputation model comprised all predictor and 
outcome variables in the analysis. We generated 50 imputed datasets and fitted Cox 
proportional models within each dataset after which estimates were pooled according 
to Rubin’s rules 10. In sensitivity analysis we repeated the analysis using a complete 
case analysis which showed identical estimates to the imputation model 
(Supplementary figure 1). To exclude the possibility that missingness at one-year was 
associated with stable or worse disease control, we modelled two sensitivity scenarios 
in which a normal-TSH and a low-TSH at one-year were assumed for patients with 
serial TSH but missing one-year TSH. These scenarios gave similar results to the 
imputation model (data not shown).  
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SUPPLEMENTARY FIGURE 1: Hazard ratios for mortality or MACE by one-year TSH, complete case analysis 
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Analysis was conducted in all patients and in 
treatment subgroups according to treatment in the first-year with antithyroid drugs (ATD) or radioactive iodine (RAI). P-int, P values for 
interaction with treatment group. Results are obtained from a complete case analysis 
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SUPPLEMENTARY FIGURE 2: FT4 profile post-diagnosis  
Longitudinal profile of FT4 concentrations after diagnosis according to treatment groups. FT4 is in multiples of the 
upper limit of the reference range (X ULN); ATD, antithyroid drugs, RAI-Grp-A, radioiodine with control of 
hyperthyroidism by 12 months, RAI-Grp-B, radioiodine without control of hyperthyroidism by 12 months 
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  FT4, pmol/L TSH, mU/L 
Laboratory Assay method, platform Reference Interval CV (%) Reference Interval CV (%) 
Cardiff and Vale      
 Jan 1998 - May 2011 CCIA, ADVIA Centaur, Bayer1 9·8–23·1 2·31 at 13·9 pmol/L 0·35 - 5·50 2·44 at 5·65 mU/L 
 May 2011 - Jan 2013 CMIA, Abbott ARCHITECT2  9·0 –19·1* <10 at all levels 0·30 - 4·40 <10 at all levels 
Cwm Taf (1)      
 Jan 1998 - March 2007 CCIA, IMMULITE 2000, DPC3  10·3–24·5 <10 at all levels 0·4 - 4·0 <5·0 at all levels 
 March 2007 - Dec 2013 ECLIA, Roche E-1704 10·3–24·5 8·2 at 8·2 pmol/L 0·4 - 4·0 2·4 at 6·67 mU/L 
Cwm Taf (2)      
 Jan 1995 – April 2011 CCIA, ADVIA Centaur, Bayer1 10·0-25·0 <10 at all levels 0·35-5·50** <10 at all levels 
 April 2011-Sept 2012 CCIA, ADVIA Centaur, Bayer1 10·0-25·0 <10 at all levels 0·35-5·50 <10 at all levels 
 Sept 2012-Dec 2013 ECLIA, Roche E-1704 10·3–24·5 8·2 at 8·2 pmol/L 0·4 - 4·0 2·4 at 6·67 mU/L 
Aneurin Bevan (1)   
 
   
                                            1998-2006 CCIA, IMMULITE 2000, DPC3  11·5–22·7 <10 at all levels 0·4 - 4·0 <5 at all levels 
 2006-2013 CMIA, Abbott ARCHITECT2  9·0–19·1 4·8% at 23·3 pmol/L 0·30 - 4·40 4·1% at 26·8 mU/L 
Aneurin Bevan (2)       
  1998—2000 MEIA, Abbott Axsym2  9·0–19·1 4·6 at 15·4 pmol/L 0·30 - 4·40 4·9 at 2·8 mU/L 
 
2000—2006 CCIA, ADVIA Centaur, Bayer1 9·8–23·1 <10 at all levels 0·35 - 5·50 <10 at all levels 
 
2007—2013 CMIA, Abbott ARCHITECT2 9·0–19·1 <10 at all levels 0·30 - 4·40 <10 at all levels 
Supplementary Table 1: Thyroid hormone assays  
CV, coefficient of variation; CCIA, competitive chemiluminescent immunoassay, CMIA, chemiluminescent microparticle immunoassay; ECLIA, 
electrochemiluminescence immunoassay; MEIA, Microparticle Enzyme Immunoassay; 1. Bayer Diagnostics, Newbury, UK; 2.  Abbott Diagnostics, Maidenhead, 
Berks, UK; 3. Diagnostics Product Corporation, Llanberis, Wales; 4. Roche Diagnostics GmbH, Mannheim, Germany, *from January to December 2013 the 
reference range for this assay was changed to 9.2—21.0 pmol/L, **from September 2009 to April 2011, reference range for this assay was 0.3-6.0 mU/L  
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Condition ICD-10 diagnosis codes Score 
Acute myocardial infarction I21, I22, I252 1 
Congestive heart failure I50 1 
Peripheral vascular disease I71, I790, I739, R02, Z958, Z959 1 
Cerebral vascular disease I60, I61, I62, I63, I65, I66, G450, G451, G452, G458, G459, G46, I64, G454, I670, 
I671, I672, I674, I675, I676, I677, I678, I679, I681, I682, I688, I69 
1 
Dementia F00, F01, F02, F051 1 
Pulmonary disease J40, J41, J42, J44, J43, J45, J46, J47, J67, J44, J60, J61, J62, J63, J66, J64, J65 1 
Connective tissue disease M32, M34, M332, M053, M058, M059, M060, M063, M069, M050, M052, M051, M353 1 
Peptic ulcer disease K25, K26, K27, K28 1 
Liver disease K702, K703, K73, K717, K740, K742, K746, K743, K744, K745 1 
Diabetes E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, E145 1 
Diabetes with complications E102, E112, E132, E142, E103, E113, E133, E143, E104, E114, E134, E144 2 
Hemiplegia or paraplegia G81, G041, G820, G821, G822 2 
Renal disease N03, N052, N053, N054, N055, N056, N072, N073, N074, N01, N18, N19, N25 2 
Cancer C0, C1, C2, C3, C40, C41, C43, C45, C46, C47, C48, C49, C5, C6, C70, C71, C72, 
C73, C74, C75, C76, C81, C82, C83, C84, C85, C883, C887, C889, C900, C901, C91, 
C92, C93, C940, C941, C942, C943, C945, C947, C95, C96 
2 
Metastatic cancer C77, C78, C79, C80 3 
Severe liver disease K729, K766, K767, K721 3 
HIV B20, B21, B22, B23, B24 6 
Supplementary Table 2: Modified Charlson Comorbidity Scores  
Reference 2,3 
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 Patients with available thyroid tests Patients with missing thyroid tests 
 All patients  Medical therapy Iodine-131 Thyroidectomy P for trend, 
treatment 
groups a 
All patients P value, 
missing vs non-
missing b 
 
n=2969  n=1950  n=796   n=223  n=1220 
Age, yrs        
 Mean + SD 47 + 16 46 + 16 50 + 16 39 + 13 <0·001 49 + 16 <0.001 
 <20 42 (1·4) 29 (1·5) 6 (0·8) 7 (3·1) <0·001 9 (0.7)  
 20-29 409 (13·8) 278 (14·3) 81 (10·2) 50 (22·4)  135 (11.1)  
 30-39 630 (21·2) 424 (21·7) 133 (16·7) 73 (32·7)  225 (18.4)  
 40-49 669 (22·5) 426 (21·9) 191 (24·0) 52 (23·3)  253 (20.7)  
 50-59 550 (18·5) 360 (18·5) 170 (21·4) 20 (9·0)  260 (21.3)  
 60-69 390 (13·1) 252 (12·9) 120 (15·1) 18 (8·1)  195 (16.0)  
 >70 279 (9·4) 181 (9·3) 95 (11·9) 3 (1·4)  143 (11.7)  
Sex        
 Female 2422 (81·6) 1596 (81·9) 633 (79·5) 193 (86·5) 0·050 992 (81.3) 0.841 
 Male 547 (18·4) 354 (18·2) 163 (20·5) 30 (13·5)  228 (18.7)  
Comorbidity         
 Absent 2564 (86·4) 1678 (86·1) 688 (86·4) 198 (88·8) 0·532 1035 (84.9) 0.198 
 Present 405 (13·6) 272 (13·9) 108 (13·6) 25 (11·2)  185 (15.2)  
TRAb IU/L 7·8 (3·2, 18·4) 6·4 (2·9, 14·0) 11·4 (4·2, 27·0) 16·4 (5·6, 37·5)  <0·001 5.8 (2.75, 12.9) <0.001 
Thyroid status        
 FT4, pmol/L 31·8 + 22·0 29·5 + 19·7 36·2 + 25·4 36·5 + 25·6 <0·001 —  
 FT4 >40 
pmol/L 
719 (24) 390 (20) 255 (32) 74 (33) <0·001 —  
Missing tests 1220 (29) 1144 (37) 33 (4) 43 (16) <0.001 —  
Supplementary Table 3: Baseline characteristics in patients with missing and non-missing thyroid function tests  
Data represents numbers (%), mean + SD, or median (interquartile range).  TRAb, TSH receptor antibody; a, P values are for trend across treatment 
categories in patients with thyroid tests. b, P values are for difference between missing and non-missing tests.  
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 ATD RAI-Group-A  RAI-Group-B P value  
Number (%) 3587 (89%) 250 (6%) 182 (5%)  
Age     
 Mean + SD 46·9 + 15·8 52·6 + 15·0 52·9 + 15·8 <0·001a, b 
 Range 18-92 19-88 20-92  
Gender     
 Male 642 (17·9%) 55 (22·0%) 41 (22·5%) 0·089 
 Female 2945 (82·1%) 195 (78·0%) 141 (77·5%)  
Comorbidity     
 Present 485 (13·5%) 35 (14·0%) 30 (16·5%) 0·728 
 Absent 3102 (86·5%) 215 (86·0%) 152 (83·5%)  
TRAbs, U/L 6·7 (3, 15·8)  11·2 (4·1, 26·6)  11·4 (4·4, 26·1)  <0·001a, b 
Radioiodine therapy     
 Dose, Mbq - 555 (546, 563) 555 (544, 566) 0·984d 
 Days from diagnosis to treatment - 108 (53, 178) 188 (88, 302) <0·001 d 
FT4, pmol/L      
 Baseline  31·2 + 21·8 35·2 + 25·2 34·8 + 21·7 <0·003a, b 
 12 months 17·4 + 9·3 15·9 + 7·3 21·5 + 10·6 <0·001a, b, c 
 Baseline – 12 months  16·1 + 23·0 21·1 + 26·9 13·9 + 21·3 <0·001b, c 
TSH at 12 months, mU/L     
 Low 770 (39·6%) 44 (18·9%) 84 (64·6%) <0·001 a, c 
 Normal 905 (46·5%) 41 (17·7%) 36 (27·7%)  
 High 272 (13·9%) 147 (63·4%) 10 (7·7%)  
Supplementary Table 4: Characteristics of patients in the one-year landmark cohort  
a ATD vs RAI-Group-A, b ATD vs RAI-Group-B, c RAI-Group-A vs RAI-Group-B; ANOVA with pairwise comparisons with Tukey’s test; d 
RAI-Group-A vs RAI-Group-B, Kruskal Wallis; data is in numbers (%), mean + standard deviation, or median (interquartile range). Excluded 
patients who had surgery in the first 12 months (n=78) or <12 months survival (n=89). 
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 All-Cause Mortality MACE 
 Events/Total, N HR (95% CI) P value Events/Total, N HR (95% CI) P value 
Whole cohort       
 ATD 145/3527 1·00 (Ref)  176/3384 1·00 (Ref)  
 RAI-Group-A 13/236 0·47 (0·27, 0·83) 0·009 17/224 0·49 (0·30, 0·81) 0·005 
 RAI-Group-B 21/174 1·52 (0·96, 2·42) 0·083 21/159 1·49 (0·94, 2·35) 0·089 
No comorbidities       
 ATD 82/3047 1·00 (Ref)  118/2982 1·00 (Ref)  
 RAI-Group-A 4/201 0·20 (0·07, 0·56) 0·002 7/195 0·25 (0·12, 0·54) 0·001 
 RAI-Group-B 13/146 1·45 (0·80, 2·63) 0·195 16/137 1·68 (0·99, 2·84)                0·052 
Age>50 yrs       
 ATD 129/1502 1·00 (Ref)  152/1387 1·00 (Ref)  
 RAI-Group-A 11/137 0·43 (0·23, 0·79) 0·007 15/127 0·46 (0·27, 0·79)  0·005 
 RAI-Group-B 19/96 1·52 (0·93, 2·48) 0·102 17/84 1·36 (0·82, 2·25) 0·236 
Age<50 yrs                                                                          
 ATD 16/2025 1·00 (Ref)  24/1997 1·00 (Ref)  
 RAI-Group-A 2/99 1·04 (0·23, 4·79) 0·963 2/97 0·74 (1·70, 3·18) 0·680 
 RAI-Group-B 2/78 1·36 (0·31, 6·09) 0·691 4/75 2·32 (0·79, 6·78) 0·125 
Supplementary Table 5: Mortality and MACE by primary treatment: excluding pregnant patients  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models.  Analysis was conducted in all patients and in subgroups 
according to treatment in the first-year. ATD, Antithyroid drugs, RAI-Group-A, radioiodine treatment with control of hyperthyroidism, RAI-Group-B, 
radioiodine treatment without control of hyperthyroidism   
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 All-Cause Mortality MACE 
 Events/Total, N HR (95% CI) P value Events/Total, N HR (95% CI) P value 
Whole cohort       
 ATD 142/3353 1·00 (Ref)  166/3215 1·00 (Ref)  
 RAI-Group-A 13/229 0·46 (0·26, 0·82) 0·009 17/218 0·50 (0·30, 0·83) 0·007 
 RAI-Group-B 21/166 1·53 (0·96, 2·44) 0·071 19/151 1·38 (0·86, 2·33) 0·184 
No comorbidities       
 ATD 82/2903 1·00 (Ref)  114/2841 1·00 (Ref)  
 RAI-Group-A 4/197 0·20 (0·07, 0·54)  0·002 7/192 0·25 (0·12, 0·54) 0·001 
 RAI-Group-B 13/139 1·44 (0·79, 2·60) 0·119 15/130 1·62 (0·94, 2·77)                                  0·082
Age>50 yrs       
 ATD 126/1408 1·00 (Ref)  142/1297 1·00 (Ref)  
 RAI-Group-A 11/131 0·42 (0·22, 0·78) 0·006 15/121 0·48 (0·28, 0·82) 0·007 
 RAI-Group-B 19/89 1·53 (0·94, 2·50) 0·089 15/77 1·23 (0·72, 2·11) 0·443 
Age<50 yrs                                                                              
 ATD 16/1945 1·00 (Ref)  24/1918 1·00 (Ref)  
 RAI-Group-A 2/98 1·02 (0·22, 4·69) 0·984 2/97 0·72 (1·67, 3·11) 0·660 
 RAI-Group-B 2/77 1·38 (0·31, 6·16) 0·673 4/74 2·31 (0·79, 6·74) 0·126 
Supplementary Table 6: Mortality and MACE by primary treatment: excluding patients with borderline TRAbs  
Patients with borderline TRAbs (1.0-1.5 IU/L) were excluded. HR (95% CI) are obtained from multivariable Cox proportional hazard regression models.  
Analysis was conducted in all patients and in subgroups according to treatment in the first-year. ATD, Antithyroid drugs, RAI-Group-A, radioiodine 
treatment with control of hyperthyroidism, RAI-Group-B, radioiodine treatment without control of hyperthyroidism   
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 Model 1 Model 2 
 HR (95% CI) P value HR (95% CI) P value 
Age, years a 1·09 (1·08, 1·10) <0·001 1·09 (1·08, 1·10) <0·001 
Sex     
 Male 1·00 Ref 1·00 Ref 
 Female  0·57 (0·43, 0·76) <0·001 0·65 (0·47, 0·90) 0·010 
Co-morbidity     
 Absent 1·00 Ref 1·00 Ref 
 Present 3·07 (2·29, 4·13) <0·001 3·30 (2·36, 4·63) <0·001 
Year of diagnosis b 0·68 (0·58, 0·79) <0·001 0·63 (0·54, 0·79) <0·001 
Baseline TRAb c  1·15 (0·99, 1·32) 0·069 1·14 (0·96, 1·35) 0·144 
Thyroid hormones     
 Baseline FT4 d  — — 0·99 (0·99, 1·00) 0·474 
 Baseline TSH  — —   
  TSH 0.1—0·4 mU/L   1·00 Ref 
  TSH <0·1 mU/L   0·99 (0·95, 1·02) 0·384 
 Serial FT4 d — — 1·40 (1·11, 1·77) 0·005 
 Serial TSH     
  Normal/High — — 1·00 Ref 
  Low — — 1·00 (0·66, 1·54) 0.980 
Treatment     
 ATD 1·00 Ref  1·00 Ref 
 RAI without hyperthyroidism control 0·91 (0·67, 1·25) 0·571 0·97 (0·70, 1·36) 0·863 
 RAI with hyperthyroidism control 0·26 (0·08, 0·82) 0·022 0·27 (0·09, 0·87) 0·028 
 Thyroidectomy 0·60 (0·15, 2·44) 0·472 0·33 (0·05, 2·39) 0·272 
Supplementary Table 7: Multivariable analysis for all-Cause mortality  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Model 1, all patients, n=4189; Model 2, patients with 
thyroid function tests, n=2969; Serial thyroid hormones and treatment were set as time-dependent covariates. Patients contributed person-years 
of treatment from diagnosis to radioiodine treatment or thyroidectomy (ATD), following radioiodine to control of hyperthyroidism (RAI without 
hyperthyroidism control), following radioiodine and control of hyperthyroidism (RAI with hyperthyroidism control), and following thyroidectomy 
(thyroidectomy).   a, HR per 5-year increase in age; b, HR per 5-year increase in diagnosis year, c, HR per 10 IU/L increase in TRAb 
concentration, d, HR per 10 pmol/L increase in FT4 concentration 
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 Model 1 Model 2 
 HR (95% CI) P value HR (95% CI) P value 
Age, years  1·08 (1·07, 1·09) a <0·001 1·08 (1·07, 1·09) a <0·001 
Sex     
 Male 1·00 Ref 1·00 Ref 
 Female  0·56 (0·44, 0·71) <0·001 0·61 (1·07, 1·09) <0·001 
Co-morbidity     
 Absent 1·00 Ref 1·00 Ref 
 Present 2·91 (2·28, 3·72)  <0·001 2·95 (2·22, 3·91) <0·001 
Year of diagnosis  0·75 (0·67, 0·85) b <0·001 0·74 (0·64, 0·86) b <0·001 
Baseline TRAb  1·04 (0·93, 1·17) c 0·493 1·06 (0·92, 1·22) c 0·404 
Thyroid hormones     
 Baseline FT4  — — 0·99 (0·99, 1·00) d 0·618 
 Baseline TSH  — —   
  TSH 0.1—0·4 mU/L   1·00 Ref 
  TSH <0·1 mU/L   0·99 (0·96, 1·01) 0·317 
 Serial FT4 — — 1·52 (1·09, 1·94) d 0·007 
 Serial TSH     
  Normal/High — — 1·00 Ref 
  Low — — 1·00 (0·89, 1·78) 0.990 
Treatment     
 ATD 1·00 Ref 1·00 Ref 
 RAI without hyperthyroidism control 1·02 (0·78, 1·34) 0·857 1·08 (·081, 1·43) 0·601 
 RAI with hyperthyroidism control 0·44 (0·20, 0·94) 0·033 0·45 (0·21, 0·96) 0·040 
 Thyroidectomy 0·35 (0·09, 1·43) 0·144 0·19 (0·03, 1·40) 0·103 
Supplementary Table 8: Multivariable analysis for MACE  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Model 1, all patients, n=4189; Model 2, patients with 
thyroid function tests, n=2969; Serial thyroid hormones and treatment were set as time-dependent covariates. Patients contributed person-years 
of treatment from diagnosis to radioiodine treatment or thyroidectomy (ATD), following radioiodine to control of hyperthyroidism (RAI without 
hyperthyroidism control), following radioiodine and control of hyperthyroidism (RAI with hyperthyroidism control), and following thyroidectomy 
(thyroidectomy).   a, HR per 5-year increase in age; b, HR per 5-year increase in diagnosis year, c, HR per 10 IU/L increase in TRAb 
concentration, d, HR per 10 pmol/L increase in FT4 concentration 
